Fragile X syndrome (FXS) is caused by a mutation that silences the fragile X mental retardation gene (FMR1), which encodes the fragile X mental retardation protein (FMRP).
Introduction
Fragile X syndrome (FXS) typically results from an inherited triplet repeat expansion mutation that induces DNA methylation-dependent silencing of the fragile X mental retardation gene (FMR1) resulting in an absence of the fragile X mental retardation protein (FMRP). [1] [2] [3] [4] [5] Recent evidence suggests that the lack of FMRP leads to aberrant synaptic plasticity, which may be a seminal mechanism underlying mental retardation and other FXS phenotypes. 6, 7 Synaptic plasticity, which either potentiates or depresses synaptic strength, is essential to learning and memory and has been well characterized in the hippocampus. 8, 9 Long-term maintenance of either potentiation or depression (LTD) relies on protein synthesis, partially occurring at the site of synaptic plasticity in dendritic spines. 10, 11 Such local protein synthesis allows for a rapid and specific response after synaptic activity. Depression of synaptic strength is mediated by at least two different pathways involving either N-methyl-Daspartate (NMDA) receptor or metabotropic glutamate receptor (mGluR) signaling. 10 Evidence indicates that FMRP has a role in mGluR signaling as it pertains to protein-synthesis-dependent synaptic plasticity because the levels of FMRP increase after mGluR activation, FMRP binds RNA, and associates with the protein synthesis machinery in dendritic spines. [12] [13] [14] In addition, fmr1-knockout mice (KO) have enhanced, protein synthesis-independent mGluR-LTD, presumably because of an increase of LTD-inducing proteins. 6, 7, 15, 16 A critical question with respect to FXS is whether the lack of FMRP during development induces permanent abnormalities in neuronal function or whether it has a dominant role in adult synaptic plasticity such as mGluR-LTD. The latter scenario would suggest that post-developmental restoration of FMRP may be therapeutic by re-establishing normal synaptic plasticity.
In this study, we sought to determine whether FMRP replacement in an adult hippocampus could rescue the KO phenotype of enhanced, paired-pulse low-frequency stimulation (PP-LFS)-induced, protein synthesisindependent, mGluR-LTD (PP-LTD). To achieve FMRP replacement, we used an adeno-associated virus (AAV)based vector. Such vectors have shown efficient neuronal transduction characteristics and have the ability to maintain robust transgene expression within the central nervous system (CNS). 17 Furthermore, AAV vectors offer a high degree of safety, as they do not integrate into the host genome, the parent virus is naturally non-pathogenic, viral coding sequence can be discarded, little immune induction occurs, and vector preparations have negligible amounts of contamination by helper virus. 17, 18 Therefore, AAV vectors provide a valuable tool for studying and potentially treating various neurological diseases, 19 and thus may also have potential to treat FXS. Our results indicate that PP-LTD is enhanced in fmr1-KO mice compared with wild-type (WT) mice and that expression of the major CNS isoform of FMRP alone is sufficient to rescue the phenotype.
Results

Expression of vectored FMRP in the CNS
Both AAV vectors that were used in this study use the chicken b-actin core promoter with elements from the cytomegalovirus immediate-early enhancer 20,21 and contain inverted terminal repeats (TR) from AAV serotype 2 (TR2) packaged in serotype 5 capsids. The fmr1-AAV (FAAV) vector contains the murine fmr1 gene encoding the major CNS isoform of FMRP, which was modified by insertion of a FLAG tag to facilitate potential protein purification and detection. The UF11 control vector is similar to the FAAV vector, but instead of fmr1, the vector contains a gene encoding the green fluorescent protein (GFP) 22 (Figure 1 ).
To assess vector transduction and confirm transgene expression in the CNS, real-time RT-PCR and immunohistochemical detection of vector-encoded FMRP was conducted. After injection of FAAV into the CNS of fmr1-KO mice, real-time RT-PCR showed a significant and robust increase (approximately 12-fold relative to WT) in fmr1-mRNA expression ( Figure 2 ). In contrast, the levels of fmr1 mRNA were unchanged by injection of UF11. Immunohistochemical detection of FMRP in hippocampal slices used for electrophysiological analysis revealed robust staining, particularly in the pyramidal cell layer of CA1, the location of PP-LTD analysis ( Figure 3 ). This robust staining corroborates the RT-PCR expression data and confirms the efficient vector delivery and the FMRP expression in hippocampal neurons.
Rescue of enhanced PP-LTD in fmr1-KO mice by the FAAV vector
Earlier work showed that PP-LTD is more robust at CA3-CA1 hippocampal synapses in fmr1-KO mice and that this enhanced form of LTD does not require protein synthesis. 7 Consistent with these findings, our analysis revealed a significant (Po0.05) enhancement of PP-LFS (1200 paired pulses delivered at 1 Hz, 50 ms inter-pulse interval, 20 min) LTD in fmr1-KO mice (n ¼ 13) relative to WT animals (n ¼ 9) observed in the presence of D,L-APV (NMDA receptor antagonist, 100 mM) and anisomycin (protein synthesis inhibitor, 20 mM) ( Figure 4a and c).
Next, we wished to assess the ability of FMRP replacement to rescue the phenotype of enhanced, protein synthesis-independent, PP-LTD in fmr1-KO mice. Therefore, KO mice were injected with the fmr1expressing vector, FAAV, or a control GFP-expressing vector, UF11. Three weeks after hippocampal injections, we measured PP-LTD in the presence of AP-5 and anisomycin. PP-LTD in control-injected mice (n ¼ 9) resembled the KO group, indicating that there was no detectable effect of tissue damage or of an AAV vector alone (Figure 4b and c). Strikingly, KO mice that received hippocampal injections of the FAAV vector (n ¼ 9) showed significantly less PP-LTD compared with uninjected KO or UF11-injected KO mice and was similar to WT PP-LTD levels (Figure 4b and c). These data indicate that the FAAV vector rescued the KO phenotype of enhanced, protein synthesis-independent, PP-LTD in fmr1-KO mice ( Figure 4c ).
Control pathways, which did not receive PP-LFS, were unchanged between groups, indicating that slice health was maintained throughout recording and that the PP-LFS protocol was necessary and sufficient for induction of LTD (Figure 4a and c). Furthermore, input-output curves were generated, which show no difference in baseline synaptic responses among the experimental groups ( Figure 4e ).
Discussion
Our principal hypothesis was that facets of FXS are treatable by a gene therapy approach, as the syndrome results from a single gene loss-of-function mutation. Furthermore, we hypothesized that restoration of adult synaptic plasticity would translate into therapeutic modifications of the CNS regardless of developmental abnormalities that occur in FXS. Therefore, we constructed an AAV vector containing the fmr1 gene encoding the major murine CNS isoform of FMRP and assessed its ability to restore functional FMRP expression in the hippocampus of fmr1-KO mice. We then tested whether FMRP replacement using the AAV vector could Figure 1 Viral vectors. Both UF11 and FAAV vectors contain TR elements from AAV serotype 2, but were packaged in serotype 5 capsids. In addition, both vectors use the chicken b-actin hybrid promoter (CBA) with regulatory elements including an enhancer from the cytomegalovirus (CMV), an exon (chicken b-actin), and a hybrid intron (chicken b-actin/rabbit b-globin). Also, both vectors contain a polyadenylation signal from the human growth hormone gene (bGH). The FAAV vector possesses cDNA encoding the major murine CNS isoform of FMRP, which has been modified to include a FLAG tag. In place of the fmr1 sequence, the UF11 vector possesses a humanized GFP gene with a simian virus 40 polyadenylation sequence (SV40 poly (A)) and a neomycin resistance gene (neoR) driven by a mutant polyoma virus enhancer (pyf441) and herpes simplex virus thymidine kinase (HSV-tk) promoter. The mGluR theory of FXS postulates that protein synthesis-dependent processes downstream of mGluRsignaling pathways in the CNS are enhanced in FXS resulting in cognitive deficits. 23 Furthermore, recent findings suggest that synaptically localized FMRP reduces steady-state levels of LTD-inducing proteins. 7 Thus, in the absence of FMRP, an excess of these proteins leads to enhanced mGluR-LTD without the need for de novo protein synthesis. Furthermore, it has been shown that KO mGluR-LTD resembles the mature form of LTD, as it is associated with a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor internalization. 7, 24 Here, we show that the FAAV vector restores FMRP expression in the hippocampus of KO mice, and rescues the phenotype of enhanced mGluR-LTD when induced by PP-LFS. In accordance with the mGluR theory of FXS, we hypothesize that vectored FMRP reduces the steadystate levels of LTD-inducing proteins likely by sequestering their respective mRNA transcripts. Therefore, similar to WT mice, FAAV-injected KO mice require de novo protein synthesis to maintain mGluR-LTD.
For transition of a gene therapy approach to clinical treatment of FXS, several challenges must be addressed. First, it must be established that the major isoform of FMRP in the CNS, accounting for approximately 40% of total FMRP, is sufficient to restore normal function or if multiple isoforms are required. This is especially critical for AAV vectors, as the virion is not capable of accommodating multiple cDNA genes encoding neither the various isoforms nor the natural fmr1 locus, which is approximately 38 kb, although multiple AAV vectors, each expressing a different isoform could be used synergistically if multiple isoforms must be expressed. Nonetheless, recent findings have shown that audiogenic seizures are reversed by expression of the major CNS isoform of FMRP in a transgenic mouse indicating that it alone is therapeutic. 25 Similarly, our results suggest that the major CNS isoform is sufficient to restore function with respect to PP-LTD. These studies provide strong evidence that restoration of the major CNS isoform of FMRP has therapeutic value for FXS and makes a gene therapy approach to the disease using AAV vectors a feasible one. Furthermore, expression of only one isoform at a time using viral vectors may be advantageous for elucidating the mechanistic properties of FMRP because it allows for each isoform to be investigated independently.
Another important consideration is that limiting expression to only the coding sequence of fmr1 may not be ideal, as it was thought that the 3 0 untranslated region (UTR) may be important for localization and regulation of the transcript, possibly by FMRP itself. 26 Such regulation would not be abrogated in our approach, as the binding site now seems to be located in the coding sequence and not in the 3 0 UTR. 26 A practical limitation for human gene therapy is that global transduction of the CNS is not feasible using current vectors. Therefore, a delivery approach such as the one used in this study that targets specific regions of the CNS responsible for specific behavioral symptoms of FXS would likely be required.
Current viral vectors are typically incapable of using endogenous promoters for expression of transgenes because of promoter shutdown. 27 Therefore, to achieve long-term expression, artificial promoters must be used, resulting in artificial transgene regulation. 17, 19 Some have suggested that expression of FMR1 using an artificial (non-FMR1) promoter would be unsuccessful in treating FXS, as normal (synaptic activity-dependent) gene expression would be abrogated. 28 However, in a recent study, a reversal of the audiogenic seizure phenotype was seen when an FMR1 gene, driven by an artificial promoter, was introduced into a KO strain by transgenic methods, 25 although other phenotypes were not. 29 Furthermore, it is likely that regulation of FMRP in the context of synaptic function does not occur at the level of transcription. Indeed, mGluR-LTD itself is not dependent on de novo transcription. 30 Rather, FMRP regulation at the level of translation and proteolysis may be critical for proper mGluR-LTD. 31 This study suggests that post-developmental overexpression of the major CNS isoform of FMRP is not deleterious, and our success in phenotypic rescue supports this conclusion. However, an earlier study has indicated that over-expression of FMRP by insertion of a yeast artificial chromosome (YAC) containing the FMR1 locus into the genome of mice leads to abnormal phenotypes. 28, 32 The differences in our findings and those using the YAC transgenic model could be explained by three key differences. First, this study used post-developmental gene replacement using a viral vector, which resulted in over-expression of FMRP in adult animals, whereas over-expression of FMRP in the YAC transgenic mouse occurred during development. Therefore, because of the potential effects of developmental over-expression of FMRP, the two studies are not directly comparable. Second, the YAC transgenic mouse expressed the human FMR1 gene in a mouse. Although the mouse and human FMRP share 97% homology, they are known to differ in mRNA binding properties. 33 Third, the YAC transgenic mouse over-expressed all isoforms of FMRP in the CNS of transgenic mice. This may result in deleterious effects on neuronal development, whereas over-expression of only the major murine CNS isoform may not. However, in the event that negative effects of over-expression become evident, a viral vector delivery strategy affords the ability to Finally, a recent study showing the rapid degradation of FMRP after mGluR activation 31 may provide support for a vector strategy, as it reveals a mechanism for maintaining steady-state levels of FMRP even in the event of over-expression. In summary, our gene therapy approach represents a viable approach to restore FMR1 gene expression in FXS, yet several challenges must be overcome before it can translate into an actual therapeutic method of treatment. Nevertheless, two critical questions about FXS have been addressed in this study. First, it seems that post-developmental restoration of FMRP expression can restore normal neuronal function as measured here. Second, our results suggest that expression of the major CNS isoform of FMRP is sufficient for this restoration of neuronal function making a gene therapy approach, and analysis of FMRP function, more straightforward. Furthermore, our data suggests that although global transduction of the CNS may not be feasible with current vectors, a targeted delivery strategy to specific brain structures can be therapeutic, and opens the door to potential therapies of the various FXS-associate behavioral deficits.
Materials and methods
Vector construction
The fmr1 cDNA for the major murine CNS isoform of FMRP was obtained from the MC2. 17 plasmid, a gift Figure 3 Immunohistochemical detection of FMRP expression by FAAV in the hippocampus. Fmr1-KO mice received three injections (1 ml per injection) of the FAAV vector in each side of the hippocampus surrounding the coordinates (À0.19 mm AP, +/À0.15 mm Lat, À0.17 mm DV, from Bregma) to ensure complete transduction. Animals were perfused 3 weeks later, and the tissue was prepared for electrophysiological analysis. After electrophysiological analysis, hippocampal slices from WT (a, b at Â 5 and Â 40, respectively), KO (c, d), and FAAV-injected KO animals (e, f) were prepared for immunohistochemical detection of FMRP using the IC3 monoclonal antibody and peroxidase/substrate visualization (brown). Sections were counterstained with hematoxylin (blue).
FMRP replacement restores synaptic function Z Zeier et al from Dr Nelson. 12 The cDNA included 123 bp upstream of the ATG start codon, all 17 exons, 2288 bp of 3 0 UTR and a polyA signal (ATTA). To facilitate cloning, a multiple cloning site was inserted upstream of the fmr1 translational start codon. Subsequently, a FLAG epitope tag was inserted between the second and third amino acid similar to an earlier report, 26 except that the NdeI restriction site located within the multiple cloning site was used instead of EcoNI. To improve translation of the fmr1 mRNA, a Kozak sequence (CCACCATG) was inserted at the start codon of fmr1, as well as a HindIII site to aid in cloning.
Owing to the limited packaging capacity of AAV vectors, only the coding sequence from HindIII to NsiI of the modified fmr1 gene was inserted into the pTR2-multiple cloning site AAV packaging plasmid, which was kindly provided by Dr Nick Muzyczka. Essential features of this plasmid include AAV(2) terminal repeat elements required for packaging, the chicken b-actin core promoter with elements from the cytomegalovirus immediate-early enhancer, 20, 34 and a polyA signal. Cloning of these plasmids was carried out in recombination-restricted Sure-2 cells to prevent the loss of repeat TR sequences. Before packaging, a SmaI digest was performed to confirm TR conservation. Vector packaging was performed by the University of Florida Powell Gene Therapy Center. Briefly, the rAAV vector plasmid containing the fmr1 coding sequence (pTR2 FLAG-fmr1) was transfected into 293 cells 35 along with the pXYZ5 plasmid, which provided AAV (serotype 2) rep and AAV (serotype 5) cap, and essential adenovirus helper functions (E4, VA, E2a) in trans. 36, 37 Crude cell lysates obtained from Gene Therapy Center were purified using an iodixanol gradient and Q sepharose column, then quantified by dot blot titration as described. 37 The control AAV vector (UF11) containing a GFP reporter gene driven by the same promoter (CBA) as the FAAV vector was kindly provided by Dr Muzyczka. 22 This vector was packaged and purified identically to the fmr1-containing construct.
Mice
Male C57Bl/6 fmr1-KO mice 15 were obtained from Dr William Greenough and maintained in standard housing on a 12-h light/dark cycle. WT C57Bl/6 mice were purchased from Harlan Sprague Dawley and maintained exactly as KO mice. All procedures for animal care and use were in accordance with AAALAC guidelines.
Stereotaxic injection
At 5 weeks of age, animals were anesthetized with ketamine (70-80 mg kg -1 ) and xylazine (14-15 mg kg -1 ). An incision was made on top of the skull along the midline and burr holes were placed in the skull. Injections of FAAV or UF11 vectors (approximately 1 Â 10 13 genomes ml -1 ) were conducted using a Kopf stereotaxic frame with a 10-ml Hamilton syringe fitted with a glass micropipette. Three 1 ml injections made around the coordinates AP 2.3 mm, L +/À1.6 mm, DV 1.5 mm (from Bregma) were administered bilaterally to maximize the area of transduction in the hippocampus (CA1 striatum radiatum). A syringe pump was used to ensure accurate delivery of vector at a rate of 0.35 ml min -1 . One minute was allowed to elapse before the injector was removed. To alleviate pain, Flunixin meglumine (1.1 mg kg -1 , IM) was administered twice a day as needed after surgery.
RNA isolation and quantification
RNA was isolated from a 2-4 mm block of CNS tissue surrounding the site of vector injection by the guanidine isothiocyanate extraction method and reverse transcribed. Fmr1 cDNA was amplified by real-time PCR using TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, INC, Foster City, CA, USA), and FAM-labeled TaqMan target-specific primer/probe (forward primer: 5 0 AGG GTG AGT TTT ATG TGA TAG AAT ATG CAG3 0 , reverse primer: 5 0 TCG TAG ACG CTC AAT TGT GAC AA3 0 , probe: 5 0 GTG ATG CTA CGT ATA ATG3 0 ). PCR reactions were run in triplicate and analyzed using Applied Biosystems 7900HT sequence detection systems. Cycle conditions used were as follows: 50 1C for 2 min (1 cycle), 95 1C for 10 min (1 cycle), 95 1C for 15 s, and 60 1C for 1 min (40 cycles). Threshold values used for PCR analysis were set within the linear range of PCR target amplification. Using the standard curve method, fmr1-cDNA expression values for each sample were calculated by extrapolation followed by normalization with the cellular cDNA for adenine phosphoribosyltransferase.
FMRP immunohistochemistry
Hippocampal slices were post-fixed in 4% paraformaldehyde at 4 1C after electrophysiological recording. The next day, the tissue was transferred to 70% ethanol, paraffin embedded, and sectioned at 5 mm. Sections were then deparafinized in xylenes and hydrated. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol, and epitope unmasking was performed for 25 min at 95 1C in citrate buffer (pH 6.0). Non-specific antibody binding was blocked with horse serum (Vector laboratories, Burlingame, CA, USA) diluted (15 ml ml -1 ) in Tris-buffered saline with Tween-20 (TBS-T) (Dako, Glostrup Denmark). Endogenous avidin and biotin activity was blocked using the Vector labs kit (SP-2001). FMRP was detected with the IC3 antibody (Milipore/ Chemicon, Billerica, MA, USA). A 1:1000 dilution was applied for 1 h in Zymed antibody diluent and then washed for 5 min in TBS-T. Biotinylated anti-mouse secondary antibody was applied at 1:200 in TBS-T with horse serum (15 ml ml -1 ) for 30 min. Vector labs Elite ABC detection kit in conjunction with the DAB substrate kit was used to visualize FMRP. Sections were counterstained with hematoxylin, dehydrated, and coverslipped using Xylamount. Images of staining were captured on a Zeiss light microscope fitted with a digital camera.
Hippocampal slice preparation
Mice were anesthetized with Halothane (Halocarbon Laboratories, River Edge, NJ, USA) and swiftly decapitated (Guillotine, myNeuroLab.com). The brains were rapidly removed and the hippocampus was sliced in the transverse plane into 400 mM sections using a tissue chopper. The slices were incubated in a holding chamber containing artificial cerebrospinal fluid (NaCl, 125 mM; KCl, 3.3 mM; KH 2 PO 4 , 1.25 mM; MgSO 4 , 1.0 mM; CaCl 2 , 2 mM; NaHCO 3 , 20 mM; glucose, 10 mM) at 22-24 1C for 60 min. The pH was maintained at 7.4 with 95% O 2 /5% CO 2 . Thirty minutes before recording, 1-2 slices were transferred to an interface recording chamber (Warner Instrument Corporation, Hamden, CT, USA) and perfused (2 ml min -1 ) with oxygenated artificial cerebrospinal fluid. Recordings were performed at 30 1C (Automatic Temperature Controller, TC-324B, Warner Instrument Corporation, Hamden, CT, USA).
Electrophysiological recordings and induction of LTD
At the beginning of each recording, two concentric bipolar stimulating electrodes (FHC Inc., Bowdoinham, ME, USA) were positioned in stratum radiatum of CA1 for stimulation of the Schaffer collateral and commissural afferents: one toward CA3 and one toward the subiculum. A glass micropipette filled with recording medium (1-3 MO) was positioned in stratum radiatum between the stimulating electrodes (B1 mm apart from each) for recording extracellular postsynaptic field potentials. A single diphasic stimulus pulse of 100 ms was alternated between pathways, such that each pathway was activated at 0.033 Hz. The above configuration allowed for recording two independent pathways. The 'test' pathway received LTD-inducing stimulation and the control pathway was used to monitor the stability and overall health of the slice. To normalize for input/ output variation among slices, we determined the FMRP replacement restores synaptic function Z Zeier et al maximal EPSP responses for each slice and adjusted the stimulus current to produce 50-60% of the maximal response. LTD was induced by using 1 Hz PP (with 50 ms inter-pulse interval, total 2400 pulses) LFS. Twenty minutes of stable baseline EPSP responses were obtained before applying the LTD-induction protocol. NMDA-LTD was eliminated by application of D, L-APV (100 mM, Sigma A5282, St Louis, MO, USA). In both cases anisomycin (20 mM) was used to prevent protein synthesis (Sigma A9789).
